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Abstract

Background: The inherent glycosidase inhibitory activity and potentially therapeutic value of the
polyhydroxylated pyrrolizidine alkaloids containing a hydroxymethyl substituent at the C-3 position have
been well documented. Belonging to this class, the naturally occurring hyacinthacine C-type alkaloids are of
general interest among iminosugar researchers. Their selective micromolar α -glycosidase inhibitory ranges
(10 - 100 μM) suggest that these azasugars are potential leads for treating type II diabetes. However, the
structures of hyacinthacine C1, C3 and C4 are insecure with hyacinthacine C5 being recently corrected.
Objective: This review presents the hyacinthacine C-type alkaloids: their first discovery to the most recent
advancements on the structures, biological activities and total synthesis. Conclusion: The hyacinthacine Ctype alkaloids are of exponentially increasing interest and will undoubtedly continue to be reported as
synthetic targets. They represent a challenging but rewarding synthetic feat for the community of those
interested in accessing biologically active iminosugars. Since 2009, ten total syntheses have been employed
towards accessing similarly related products but only three have assessed the glycosidase inhibitory activity of
the final products. This suggests the need for an accessible and universal glycosidase inhibitory assay so to
accurately determine the structure-activity relationship of how the hyacinthacine C-type alkaloids inhibit
specific glycosidases. Confirming the correct structures of the hyacinthacine C-type alkaloids as well as
accessing various analogues continues to strengthen the foundation towards a marketable treatment for type
II diabetes and other glycosidase related illnesses.
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1. PYRROLIZIDINE ALKALOIDS
Pyrrolizidine alkaloids, particularly those that contain a
hydroxymethyl substituent at C-1 (figure 1), have been of
exponentially growing interest since the 1960s.[1]

Figure 1. General structure for pyrrolizidine alkaloids.
Figure 2. Pyrrolizidine alkaloids heliotrine and lasiocarpine.
Their appreciation is largely a result of the increasing
number of deaths to livestock that have consumed plants rich
in pyrrolizidine alkaloids.[1] A memorable example occurred
in Australia in the late 1970s, whereby a large number of
chicken poisonings were reported.[2] On closer inspection,
researchers found that the ill-thrift, ascites and degenerative
lesions on the chickens, were the result of a commercial
poultry feed containing heliotrine and lasiocarpine (Figure
2): pyrrolizidine alkaloids found in the seeds of
Heliotropium stenophyllum.[2] However, it is more alarming
that many cases of liver disease and cancer in humans have
been the direct result of pyrrolizidine alkaloid
consumption.[3-6] This wide spread occurrence is not
surprising since there have been recorded findings of
pyrrolizidine alkaloids detected in wheat flour, honey and
also cow’s milk.[7-9] At least from an economic point of
view, it remains important that improved methods of
detection, chromatographic separation and chiefly, natural
product characterization are continually explored. In the
early 1980s, pyrrolizidine alkaloids were deemed pernicious
upon ingestion and were consequently flagged as a worldwide health concern.[1] Their toxicity is a result of the 1,2unsaturated bond, in combination with an ester at the C-9
position.[1] After consumption, hepatic mixed function
oxidases convert these pyrrolizidine alkaloids to their
counter pyrrole derivatives. These metabolic products are
highly reactive and can scar various organs in the body,
particularly rich in thiol containing amino acids.[10, 11]
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During this time, only a few examples existed of
pyrrolizidine alkaloids that displayed anti-tumor[12] and
neuromuscular blocking[13] activities and so this class of
alkaloid was generally thought to be toxic. However, by the
late 1980s, this view drastically changed after the discovery
of the polyhydroxylated pyrrolizidine alkaloids containing a
hydroxymethyl substituent at the C-3 position.[14] Alexine
(Figure 3) was the first compound of this type to be isolated
from natural sources, more specifically, the legume Alexia
leiopetala.[14] Its structure was unequivocally confirmed by
X-ray crystallography[14] and just a few months later, its C7a epimer (also crystalline), australine, was reported as a
constituent of Castanospermum australe seeds (Figure
3).[15] Following these discoveries, a number of closely
related epimers were also isolated from C. australe.[16-19]
Interestingly, alexine and australine along with their related
epimers displayed notable anti-viral properties as well as low
IC50 values towards specific glycosidases.[14, 15] These
findings
attracted
significant
attention
to
the
polyhydroxylated pyrrolizidine alkaloids, as contrary to their
non-hydroxylated analogues, they proved to be medicinally
useful.
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Figure 3. Polyhydroxylated pyrrolizidine alkaloids
containing a hydroxymethyl substituent at C-3, alexine and
its C-7a epimer australine.
The polyhydroxylated pyrrolizidine alkaloids unique
structure and high oxidation level gives rise to their reported
anti-viral properties and other medicinal applications such as
treatment for diabetes, obesity and cancer.[20, 21] Their
affinity for glycosidases is a result of their mimicry of
pyranosyl and furanosyl moieties of carbohydrates. The
strength and specific inhibition is largely dependent on the
shape, size and stereoconfiguration as well as the target
glycosidase. Before the discovery of alexine and australine,
it was generally accepted that glycosidase inhibitors were
restricted in Nature and so the search for related analogues
became of increasing interest for medicinal chemists.[15],
[22-25]
It was therefore an exciting discovery when the first
pentahydroxylated pyrrolizidine alkaloid, casuarine, was
isolated from the bark of Casuarina equisetifolia L (Figure
4) reported by Nash et al. in 1994.[26] Nash and colleagues
were initially interested in the bark of C. equisetifolia L
because of its traditional use as a medicine to treat diarrhoea,
dysentery and colic.[26, 27] Perhaps a more convincing
reason for Nash et al. to examine this natural source, was
due to previous reports of prescribed C. equisetifolia L bark
extract for the treatment of breast cancer in Western
Samoa.[26] Their investigation started with an GC-MS
analysis of the extract, where a pentahydroxy- nitrogencontaining species, later established to be casuarine, was
identified to be one of the major compounds present.
Moreover, it contained the highest oxidation level to be
found in any related naturally occurring iminosugar. Its
analogous structure to alexine and australine led researchers
to suspect it contained inherent glycosidase inhibitory
activity. This was confirmed to be correct after various
glycosidase inhibition tests.[26]

Figure 4. Polyhydroxylated pyrrolizidine alkaloid casuarine.
Casuarine has also been identified as a common constituent
within the leaves and seeds of Eugenia jambolana, a plant
native to India known particularly for its various medicinal
uses including the management of diabetes and bacterial
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infections.[28] Although initially labelled as uniflorine A
and B, it was later corrected that casuarine along with its C-6
epimer were the biologically active constituents isolated in
2000 from the leaves of a similar species Eugenia uniflora
(Figure 5).[29-35] The only other naturally occurring
casuarine epimer reported in the literature is the C-3 epimer
which was isolated from Myrtus communis L. in 2006 by
Fleet et al.[36] With respect to casuarine, its notably weaker
inhibition of α-D-glucoside is a result of its single
stereochemical difference.[36]

Figure 5. Casuarine derivatives 6-epi-casuarine and 3-epicasuarine.
2. HYACINTHACINE ALKALOIDS
One recently discovered subclass of polyhydroxylated
pyrrolizidine alkaloid that has attracted considerable
attention for their inherent glycosidase inhibitory activities
are the hyacinthacine alkaloids. Despite their analogous
structure to casuarine, alexine and australine, these alkaloids
have been named after their original source, namely the
Hyacinthaceae subfamily within the Asparagaceae.[37]
Shown in Figure 6, the hyacinthacine alkaloids can be
divided into three classes: Hyacinthacine A, B and C;
whereby the letter assignment denotes whether 0, 1 or 2
hydroxy/hydroxymethyl substituents are found on the B-ring
of the alkaloid, respectively.

Figure 6. Hyacinthacines A1, B1, C1, containing 0, 1 and 2
hydroxy or hydroxymethyl substituents on the B-ring of the
pyrrolizidine, respectively.
The discovery of the hyacinthacine alkaloids can be traced
back to the late 1960s and is considered an unprecedented
finding, largely because Asparagaceae is unrelated to the
Leguminosae, Casuarinaceae and Mytaceae plant
families.[38] In 1967 a report from The Veterinary Record
written by Thursby-Pelham, detailed the toxicological effects
on livestock after consuming Hyacinthoides non-scripta.[39]
More specifically, Thursby-Pelham found that ingestion led
to abdominal pain and dysentery in horses and lethargy and
dullness in cows.[39] The plants metabolites however
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remained a mystery until 1997, where, prompted by this
report and perhaps also the availability of this material, Fleet
et al. identified the presence of five pyrrolidine alkaloids
present in the ethanolic fraction of the leaves.[40] This was
the first report of any such alkaloids from the Hyacinthaceae
species and although the plant was considered detrimental to
livestock health, Fleet et al. were able to demonstrate that the
isolated pyrrolidine alkaloids were potential therapeutic
leads. Glycosidase inhibition studies of these isolates found
that they might serve as useful chemotherapeutic agents
against cancers, viruses and also diabetes.[38]
2.1. Hyacinthacine isolation and biological activities
Two years after this novel finding, several of the same
authors led by Asano, reported their investigation into the
fruits and stalks of the H. non-scripta.[41] To further explore
the natural abundance of similar compounds, their research
also detailed the analysis of the bulbs of a related species,
Scilla campanulata.[41]
In addition to the isolation of six pyrrolidine alkaloids, three
novel polyhydroxylated pyrrolizidine alkaloids labelled as
hyacinthacines were reported (See Table 1).[41] More
specifically, from the 50% ethanoic extracts of the H. scripta
stalks, hyacinthacine C1 was isolated, and from the 50%
ethanoic extract of the S. campanulata bulbs, hyacinthacine
B2 was isolated.[41] Hyacinthacine B1 was common in both
plants and thus found as a constituent in both extracts.[41]
Although not necessarily potent, these three alkaloids gained
considerable interest for their selective glycosidase
inhibition. Hyacinthacine B1 and B2 both displayed weak
inhibition of almond β-glucosidase (IC50 values of 320 µM
and 100 µM, respectively) and bovine liver β-galactosidase
(IC50 values of 110 µM and 160 µM, respectively). Both
alkaloids also showed selective inhibition for rat intestinal
lactase β-galactosidase, however hyacinthacine B2 proved far
more active (IC50 = 3.6 µM) than hyacinthacine B1 (IC50 =
270 µM). Interestingly, hyacinthacine C1 proved moderately
active against the amyloglucosidase of Aspergillus niger
(IC50 = 84 µM), whereas hyacinthacine B1 and B2 displayed
no inhibition for these two glycosidases.
Given these noteworthy glycosidase inhibitory activities, the
therapeutic potential warranted further investigation of the
hyacinthacine alkaloids. Since there had not yet been a
proven synthetic route to access these novel structures,
natural product investigation was the only viable option. To
increase the chance of finding similar novel hyacinthacine
alkaloids, the same authors reported in 2000, their
investigation into the bulbs of the related Muscari
armeniacum whereby they identified four novel
hyacinthacine type alkaloids.[42] More specifically, Asano
and co-workers successfully isolated (from 60% ethanoic
extracts) hyacinthacine C1 as well as new Hyacinthacines A1,
A2, A3 and B3 (See Table 1).[42] When tested against a panel
of glycosidases, hyacinthacines A1, A2, A3 and B3 displayed
weak to moderate activity against rat intestinal lactase βgalactosidase (IC50 values of 4.4 µM, 73 µM, 160 µM and 18
µM, respectively) and also A. niger amyloglucosidase (IC50
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values of 25 µM, 8.6 µM, 17 µM and 51 µM, respectively).
Hyacinthacine A1 proved to be the only alkaloid active
against rat epididymis α-L-fucosidase (IC50 = 46 µM) and
also rice α-glucosidase (IC50 = 240 µM). Hyacinthacine A1
and A2 also displayed activity against almond β-glucosidase
with IC50 values of 250 µM and 150 µM, respectively.[42]
Despite what could be considered a small compound library,
Asano and co-workers remarked on the difficulty to predict
the specificity and potency of glycosidase inhibition, based
on absolute configuration and also the degree of substitution
on the pyrrolizidine ring.[42] Concluding statements from
this body of work highlighted the need for a variety of highly
oxygenated or substituted pyrrolizidine alkaloids to better
understand the structural requirements for glycosidase
inhibtition.[42] Concurrently, glycosidase inhibitors were
also receiving considerable attention as therapeutic agents. In
addition to potential treatment for NIDDM (type II diabetes),
glycosidase inhibitors were also established as possible
treatments for tumor metastasis, viral infections, and various
lysosomal storage disorders.[20, 43-47] For these reasons,
investigation into the hyacinthacine type alkaloids also
received increased attention and resulted in perhaps the most
profitable recordings of novel hyacinthacine alkaloids
isolated from a single species to date by Asano et al. in
2002.[48] Their report detailed the analysis of the bulbs of
the related Scilla sibrica that were originally purchased from
a flower shop in 1999. Specifics of this report include 9 kg
of S. sibirica bulbs being homogenized in 60% aqueous
ethanol, and further extracted to give seven new
hyacinthacine alkaloids appropriately named hyacinthacines
A4, A5, A6, A7, B4, B5 and B6 (See Table 1).[48] Although the
majority of these hyacinthacine alkaloids proved relatively
inactive towards the selected panel of glycosidases, they still
added to the understanding of the structure-activity
relationships of these and related compounds. In summary,
the only active hyacinthacine alkaloids were A5, B4, and B5,
where they showed inhibitory activity towards the
amylglucosidase of A. niger with IC50 values of 110 µM, 89
µM and 110 µM, respectively. In addition to this,
hyacinthacine B4 displayed a moderate inhibition of bovine
epididymis α-L-fucodisase with an IC50 value of 23 µM.[48]
Two years later, Asano and co-workers reported findings of
long side chain pyrrolidines and pyrrolizidines in a closely
related Asparagaceae, Scilla peruviana.[49] Asano et al.
isolated three novel hyacinthacine A1-type related alkaloids
along with one novel australine type related alkaloid.[49]
These long-chain hyacinthacine derivatives were isolated
from 5 kg of the bulbs using 50% aqueous ethanoic extracts
and
were
accordingly
named
α-5-C-(3hydroxybutyl)hyacinthacine
A1,
α-5-C-(1,3dihydroxybutyl)hyacinthacine
A 1,
α-5-C-(1,3,4trihydroxybutyl)hyacinthacine
A1
and
α-5-C-(3hydroxybutyl)-7-epi-australine (See Table 1).[49] When
tested against a panel of glycosidases, α-5-C-(1,3dihydroxybutyl)hyacinthacine
A1
and
α-5-C-(3hydroxybutyl)-7-epi-australine displayed relatively good
activity against yeast α-glucosidase (IC50 values of 3.6 µM
and 6.6 µM, respectively), however only the former alkaloid,
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along with α-5-C-(1,3,4-trihydroxybutyl)hyacinthacine A1,
proved relatively low inhibition against almond βglucosidase and C. saccharolyticum β-glucosidase with IC50
values of 9.5 µM, 25.4 µM and 5.1 µM, 11.4 µM,
respectively.[49]
The most recent addition to the naturally occurring
hyacinthacine alkaloids is the 2007 reporting of six new
isolates from Scilla socialis.[50] Kato and co-workers
initially purchased plants of S. socialis in 2003 and
cultivated this species in a heated greenhouse. Once grown,
2.3 kg of the plant bulbs were homogenized in a 50% ethanol
solution and further investigated whereby α-5-C-(3hydroxybutyl)hyacinthacine A2, Hyacinthacine B7, C2, C3, C4
and C5 were isolated and tested against a panel of selected
glycosidases (See Table 1). Of these results, hyacinthacine
C2, C3 and C5 proved noteworthy activity against C.
saccharolyticum β-glucosidase with IC50 values of 13 µM,
25 µM and 48 µM, respectively. Hyacinthacine C4 proved to
be the only active compound against rice α-glucosidase (IC50
= 110 µM), but shared similar activities with hyacinthacine
C5 against rat α-glucosidase (IC50 = 45 µM and 77 µM,
respectively) and the amyloglucosidase of A.niger (IC50 = 57
µM for both C4 and C5). Hyacinthacine C3 displayed a
unique inhibition of bovine liver β-galactosidase with an IC50
value of 52 µM, whilst hyacinthacine C2 proved the only
alkaloid capable of inhibiting human placenta α-L-fucosidase
with an IC50 value of 17 µM.[50]
2.2. Current issues with the hyacinthacine alkaloids
Excluding the three long-chain hyacinthacine A-type
analogues, 19 hyacinthacine type alkaloids have been
isolated and reported between 1999 and 2007. In most cases,
2D NMR experiments (gCOSY, HSQC, HMBC) were the
sole basis of structure elucidation. Moreover, NOE
correlation as well as 3JH,H coupling patterns and constants
were used to determine the relative configuration but were
limited such that they were unable to identify the absolute
configuration of the isolated hyacinthacines. With no X-ray
crystallographic structures of these complex natural isolates,
this has understandably led to inconsistencies among the
hyacinthacines and suggests that their assigned
configurations are not secure. An immediately obvious
example of this can be seen in the proposed structures of
hyacinthacines C1 and C4. Although reported nearly eight
years apart, both alkaloids were assigned with identical
structures despite their prominent differences in both 1H and
13
C NMR spectroscopic data and their optical rotations.
Despite plausible NOE correlations presented for both
structures (Figure 7), the aforementioned differences
between the spectroscopic data suggests at least one of these
structures to be incorrect.[41, 50]
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Figure 7. The NOE correlations reported for hyacinthacine
C1[41] and C4.[50]
Therefore, to confirm their structures, including the proposed
relative and absolute configurations, the hyacinthacine
alkaloids have been of recent interest for total synthesis.
Furthermore, total synthesis also allows access to the core
structure of these complex alkaloids and so presents a great
significance to the large community interested in the
preparation of glycosidase inhibitors and consequent
therapeutic iminosugars.
To date, fourteen of the natural hyacinthacines, A1, A2, A3,
A6, A7, B1, B2, B3, B4, B5, B7, C2, C3 and C5 have been
synthesized, along with their related epimers and
enantiomers.[51-64] At this point, the authors note that an
increasing number of reports suggest the confirmation of
hyacinthacine A5 through methods of total synthesis.[61, 63,
65] To the best of our knowledge, hyacinthacine A5 has not
yet been synthesized and although epimers of the structure
have been reported,[66] the absolute configuration of the
natural isolate is still yet to be confirmed. In addition to the
aforementioned issues, recent synthetic studies have also
revealed that the original structures proposed for
hyacinthacine B7, C3 and C5 are incorrect.[58-62] It therefore
becomes apparent that structural revision of the original
isolates is necessary because as demonstrated in the earlier
table, hyacinthacine alkaloid epimers determine the degree
of specificity as well as the potency for the inhibition of
various glycosidases.
2.3. Total syntheses of the hyacinthacine alkaloids
Each subclass of the hyacinthacine alkaloids displays
relatively low glycosidase inhibitory activities and so merits
their total synthesis. Relative to A-type hyacinthacines, both
B and C-type alkaloids have a greater constitutional
complexity and as a result, have led to a greater number of
insecure structural assignments. Synthetic work towards
hyacinthacine A and B-type alkaloids has been included in a
number of reviews,[67-69] with a comprehensive analysis
completed in 2012 by Pyne et al.[70] The hyacinthacine Ctype alkaloids on the other hand have attracted considerable
interest and there has been a number of publications towards
their synthetic work that has not yet been summarised. When
considered from a structural point of view, the hyacinthacine
C-type alkaloids are the most diverse subclass of the
hyacinthacines. They contain at least six possible stereogenic
centres, which means that there is a minimum of 32 unique
possible diastereomers (plus their enantiomers) that can
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contain a 3-hydroxymethyl-5-methylpyrrolizidine-1,2,6,7tetraol core. Their high degree of oxidation presents a
remarkably analogous structure to glucose and is therefore
an enticing, but challenging synthesis for chemists interested
in accessing medicinally useful iminosugars. For these
reasons, the remainder of this chapter will largely focus on
the hyacinthacine C-type alkaloids and will aim to deliver a
comprehensive and collective review of all the different
synthetic approaches towards this subclass of hyacinthacine.
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Table 1: Concentration (µM) of the naturally isolated hyacinthacine alkaloids giving 50% inhibition of various glycosidases
(IC50 values)
IC50 (µM)

Hyacinthacine A1

Hyacinthacine A2

Hyacinthacine A3

Hyacinthacine A4

-a
240
NIb
-

NI
NI
-

NI
NI
-

NI
NI
NI
NI

250
-

150
-

NI
-

-

-

-

-

-

-

-

-

-

β-galactosidase
Bovine liver
Rat intestinal lactase
Rat epididymis

4.4
-

73
-

160
-

NI
-

α-mannosidase
Jack bean
Rat epididymis

NI
-

NI
-

NI
-

-

β-mannosidase
Snail
Rat epididymis

390

1000

NI

NI

α-L-fucosidase
Bovine epididymis
Rat epididymis
Human placenta

46
-

NI
-

NI
-

NI
-

α,α-trehalase
Porcine kidney

NI

260

NI

-

amyloglucosidase
Aspergillus niger

25

8.6

17

NI

-

NI

enzyme
α-glucosidase
Yeast
Rice
Rat intestinal maltase
Rat liver lysosome
β-glucosidase
Almond
Caldocellum
saccharolyticum
Human Placenta
α-galactosidase
Coffee beans

α-L-rhamnosidase
Penicillium
decumbens
a
b
“-” : Not tested, NI : No inhibition (less than 50 % inhibition at 1000 µM)

NI
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IC50 (µM)
Hyacinthacine A5

Hyacinthacine A6

Hyacinthacine A7

Hyacinthacine B1

NI
NI
NI
NI

NI
NI
NI
NI

NI
NI
NI
NI

NI
NI
-

-

-

-

320

NI

NI

NI

520

-

-

-

-

-

-

-

-

NI
-

NI
-

NI
-

110
270
-

α-mannosidase
Jack bean
Rat epididymis

-

-

-

-

β-mannosidase
Snail
Rat epididymis

NI

NI

NI

NI
-

α-L-fucosidase
Bovine epididymis
Rat epididymis
Human placenta

NI
-

NI
-

NI
-

NI
-

-

-

-

NI

110

NI

NI

NI

NI

NI

NI

-

enzyme
α-glucosidase
Yeast
Rice
Rat intestinal maltase
Rat liver lysosome
β-glucosidase
Almond
Caldocellum
saccharolyticum
Human placenta
α-galactosidase
Coffee beans
β-galactosidase
Bovine liver
Rat intestinal lactase
Rat epididymis

α,α-trehalase
Porcine kidney
amyloglucosidase
Aspergillus niger
α-L-rhamnosidase
Penicillium
decumbens
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Hyacinthacine B2

Hyacinthacine B3

Hyacinthacine B4

Hyacinthacine B5

NI
NI
-

NI
NI
-

NI
NI
NI
NI

NI
NI
NI
NI

100

NI

-

-

490

-

NI

NI

-

-

-

-

-

-

-

-

160
3.6
-

18
-

NI
-

NI
-

α-mannosidase
Jack bean
Rat epididymis

-

NI
-

-

-

β-mannosidase
Snail
Rat epididymis

NI
-

NI

NI

NI
-

α-L-fucosidase
Bovine epididymis
Rat epididymis
Human placenta

NI
-

850
-

23
-

NI
-

α,α-trehalase
Porcine kidney

NI

NI

-

-

amyloglucosidase
Aspergillus niger

NI

51

89

110

-

-

NI

NI

enzyme
α-glucosidase
Yeast
Rice
Rat intestinal maltase
Rat liver lysosome
β-glucosidase
Almond
Caldocellum
saccharolyticum
Human placenta
α-galactosidase
Coffee beans
β-galactosidase
Bovine liver
Rat intestinal lactase
Rat epididymis

α-L-rhamnosidase
Penicillium decumbens
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IC50 (µM)

Hyacinthacine B6

Hyacinthacine B7

Hyacinthacine C1
(1999)

Hyacinthacine C2

NI
NI
NI
NI

NI
NI
-

NI
NI
-

NI
NI
-

-

-

NI

-

NI

NI

NI

13

-

-

-

-

-

NI

-

NI

NI
-

NI
-

NI
NI
-

370
-

α-mannosidase
Jack bean
Rat epidiymis

-

NI
-

-

NI
-

β-mannosidase
Snail
Rat epididymis

NI

-

NI
-

-

α-L-fucosidase
Bovine epididymis
Rat epididymis
Human Placenta

NI
-

NI

NI
-

17

-

-

NI

-

amyloglucosidase
Aspergillus niger

NI

270

84

550

α-L-rhamnosidase
Penicillium decumbens

NI

-

-

-

enzyme
α-glucosidase
Yeast
Rice
Rat intestinal maltase
Rat liver lysosome
β-glucosidase
Almond
Caldocellum
saccharolyticum
Human placenta
α-galactosidase
Coffee beans
β-galactosidase
Bovine liver
Rat intestinal lactase
Rat epididymis

α,α-trehalase
Porcine kidney
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IC50 (µM)

Hyacinthacine C3

Hyacinthacine C4
(2007)

Hyacinthacine C5

α-5-C-(3hydroxybutyl)hyacint
hacine A1

NI
NI
-

110
45
-

NI
77
-

NI
NI
NI
-

-

-

-

49

25

660

48

136

-

-

-

NI

α-galactosidase
Coffee beans

NI

NI

NI

NI

β-galactosidase
Bovine liver
Rat intestinal lactase
Rat epididymis

52
-

890
-

900
-

NI
NI

α-mannosidase
Jack bean
Rat epidiymis

NI
-

NI
-

NI
-

NI

β-mannosidase
Snail
Rat epididymis

-

-

-

NI

NI

NI

NI

NI
-

-

-

-

-

870

57

57

-

-

-

-

NI

enzyme
α-glucosidase
Yeast
Rice
Rat intestinal maltase
Rat liver lysosome
β-glucosidase
Almond
Caldocellum
saccharolyticum
Human placenta

α-L-fucosidase
Bovine epididymis
Rat epididymis
Human Placenta
α,α-trehalase
Porcine kidney
amyloglucosidase
Aspergillus niger
α-L-rhamnosidase
Penicillium decumbens
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IC50 (µM)

α-5-C-(1,3dihydroxybutyl)hy
acinthacine A1

α-5-C-(1,3,4trihydroxybutyl)hyaci
nthacine A1

α-5-C-(3hydroxybutyl)hyaci
nthacine A2

α-5-C-(3hydroxybutyl)-7-epiaustraline

3.6
300
350
-

650
390
NI
-

NI
NI
-

6.6
NI
NI

9.5

25.4

-

NI

5.1

11.4

NI

200

NI

NI

-

NI

α-galactosidase
Coffee beans

NI

NI

NI

NI

β-galactosidase
Bovine liver
Rat intestinal lactase
Rat epididymis

830
NI

920
NI

NI
-

320
NI

α-mannosidase
Jack bean
Rat epididymis

680

NI

NI
-

NI

β-mannosidase
Snail
Rat epididymis

NI

NI

-

NI

α-L-fucosidase
Bovine epididymis
Rat epididymis
Human Placenta

NI
-

NI
-

NI

NI
-

α,α-trehalase
Porcine kidney

-

-

-

-

amyloglucosidase
Aspergillus niger

-

-

180

-

180

NI

-

NI

enzyme
α-glucosidase
Yeast
Rice
Rat intestinal maltase
Rat liver lysosome
β-glucosidase
Almond
Caldocellum
saccharolyticum
Human placenta

α-L-rhamnosidase
Penicillium decumbens
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2.4. Yoda et al. 2009
The first synthesis of hyacinthacine C-type alkaloids was the
synthesis of hyacinthacine C2 and C3 along with their C5epimers reported by Yoda et al. in 2009.[60] This synthesis
was an initial attempt to reveal information regarding
structure-activity relationships between the hyacinthacine Ctype alkaloids and their inhibition against various
glycosidases. Their synthetic strategy (Scheme 1) starts with
the preparation of the N-Boc lactam 1 from commercially
available (S)-(–)-2-pyrrolidone-5-carboxylic acid. The N-Boc
lactam 1 was subjected to a Grignard addition followed by a
1,2-reduction of the resulting unsaturated ketone formed by
pyrrolidinone ring opening to give the corresponding allyl
alcohol. Subsequent mesylation-cyclization then afforded the
N-Boc-2 product. Next, the Boc protecting group was
replaced with Cbz in a high yielding, three step, procedure to
give N-Cbz-3. The olefin moiety of N-Cbz-3 was then
subjected to oxidative cleavage with OsO4 and NaIO4 to give
aldehyde 4 as a single isomer. A Reformatsky-type allylation
of 4 returned a 79:21 separable mixture of the alcohols 5a
and 5b, respectively. To establish the methodology, alcohol
5a then underwent TBS protection of the hydroxy group
followed by a non-selective dihydroxylation of the terminal
olefin moiety. The inseparable diol mixture was then
subjected to a selective TBS protection of the primary
alcohol, affording a high yield (92%) of a 1:1 mixture of
separable diastereomers 6a and 6b. In separate reactions,
mesylation of the secondary alcohols of 6a and 6b followed
by Cbz deprotection resulted in concerted cyclization to give
the pyrrolizidines 7a and 7b. Individual global deprotection
of both pyrrolizidines afforded hyacinthacine C2 along with
its epimer, 5-epi-hyacinthacine C2 10 in 72% and 71%
yields, respectively. Having established the synthetic
pathway to hyacinthacine C2, Yoda and co-workers
employed a similar synthetic methodology to alcohol 5b
where they also successfully synthesized hyacinthacine C3
along with its epimer, 5-epi-hyacinthacine C3 11. When
compared with the spectroscopic data of the natural
isolates,[50] Yoda et al. confirmed only the structure for
natural hyacinthacine C2 was correct. They found that the
characterization data of their synthetic sample of
hyacinthacine C3 was inconsistent with the corresponding
natural product.
2.4. Tamayo et al. 2009
At around the same time as Yoda et al., Tamayo and coworkers published their work detailing the synthetic
approach to making analogues of hyacinthacines C2/3 from
the arabinose derived nitrone 12 (Scheme 2).[71] Their
synthesis began with the 1,3-dipolar cycloaddition of the
chemoenzymatically prepared 3-buten-1,2-diol derivatives
13a or 13b to nitrone 12 to afford cycloadducts 14 or 15,
respectively. At this stage, methodological probing was
performed with the pyrroloisoxazolidine 14, which was

Principal Author Last Name et al.

subsequently converted into the mesylate 16. Compound 16
underwent an N-O reduction with Zn/AcOH, which after a
basic work up, spontaneously cyclized to give the
pyrrolizidine 18. Deacetylation to give 19, followed by a
catalytic hydrogenation under acidic conditions afforded the
final product 20. After access to the pyrrolizidine core was
established, Tamayo and co-workers focused their attention
on cycloadduct 15. More specifically, deacetylation of 15,
followed by a TBDPS protection of the primary alcohol
afforded 17 in near quantitative yields. Using similar
methodology
(mesylation, N-O
reduction, global
deprotection), the 5-epimer 24 was obtained. Although they
were not assessed as potential glycosidase inhibitors, access
to these highly oxygenated iminosugars is still important for
the broader community interested in synthesizing complex
aza-sugars.
2.5. Tamayo et al. 2010
At this stage, hyacinthacines C1, C4 and C3 proved to be
insecure in their structural assignment. Their glycosidase
inhibitory activities proved noteworthy, but difficult to
predict, especially due to these inconsistencies. For these
reasons, Tamayo and co-workers were led to investigate and
report the synthesis of unnatural 7a-epi-hyacinthacine C1 36
and 5,7a-di-epi-hyacinthacine C1 37 in 2010.[72] From their
previous work towards the synthesis of hyacinthacine A-type
alkaloids, [73] Tamayo et al. recognized that using the
common precursor, the ,-unsaturated ketone 25, would
afford access to both hyacinthacine C-type alkaloids
(Scheme 3). More specifically, 25 was subjected to a
catalytic dihydroxylation using OsO4 and NMO to afford a
single diol diastereomer 26 in high yield. The high
diastereoselectivity achieved is a result of the steric
hindrance created by both the Boc protecting group at the
amino moiety as well as the benzyl groups at C-4 and C-3.
Diol 26 was then acetylated in good yield to afford the di-Oacetylated 27, which was subsequently reduced with NaBH4
to afford a separable mixture of alcohols 28 and 29 in a 1:1
ratio (isolated yields of 25% and 22%, respectively). To
prepare the pyrrolizidine core, alcohols 28 and 29 underwent
separate mesylation reactions, followed by an acid-catalysed
N-Boc deprotection to give the secondary amines 32 and 33,
respectively. After heating at reflux in THF under basic
conditions, both amines cyclised to give their respective
pyrrolidine cores. To both pyrrolizidine mixtures was then
added MeONa in MeOH to facilitate a one-pot debenzoyland deacetylation to afford triols 34 and 35, respectively. A
final O-benzyl deprotection of 34 and 35 revealed the desired
hyacinthacine C-type analogues, 7a-epi-hyacinthacine C1 36
and 5,7a-di-epi-hyacinthacine C1 37, respectively. Although
neither were able to resolve the structural discrepancies in
the literature, access to stereogenic variations of the heavily
hydroxylated pyrrolizidine core proves important. Their
therapeutic potential remains unclear as these compounds
were not assessed for their glycosidase inhibition.
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Scheme 1. The first total synthesis of hyacinthacine C2 and proposed structure of C3 and their C5 epimers 10 and 11,
respectively by Yoda et al.[60]
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Scheme 2. The total synthesis of unnatural hyacinthacine C2/3 analogues 20 and 24 by Tamayo et al.[71]
2.6. Yu et al. 2011
In the following year, Yu et al. published their findings
regarding the synthesis of (–)-hyacinthacine C5, 6-epi-(–)hyacinthacine C5 and 7-epi-(–)-hyacinthacine C5 from the Larabinose derived cyclic nitrone 38 (Scheme 4).[61] This not
only expanded the number of hyacinthacine C-type
analogues synthesized, but it was also the first synthesis of
the enantiomer of natural isolate hyacinthacine C5. Their
synthesis began with the addition of the lithiated dithiane 39
to the cyclic nitrone 38 which returned the stereoselective
hydroxylamine intermediate 40. Compound 40 was then
subjected to Cope-House cyclization conditions which

afforded the separable pyrrolizidine N-oxides 41 and 42 in a
1:1 ratio (55% combined yield). Pyrrolizidine N-oxides 41
and 42 were then separately reduced using Zn-HOAc to
afford the pyrrolizidines 43 and 44, respectively. Initially
focusing on the enantiomer of hyacinthacine C5, the
dithioketal moiety of pyrrolizidine 43 was hydrolysed to its
corresponding ketone, which was then selectively reduced to
the corresponding diol 45 in an overall 31% yield.
Subsequent debenzylation revealed the final product as (–)hyacinthacine C5. Turning their attention to the related
epimers, Yu and colleagues initially protected the free
hydroxy moiety in 43 using MOMCl, followed by hydrolysis
of the dithioketal to give the corresponding ketone in 61%
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yield. A stereoselective reduction of the ketone with NaBH4
afforded two separable diastereoisomers favouring the
desired alcohol 48 in a 5:1 ratio with an overall high yield
(95.5%). Global deprotection of the MOM and the O-benzyl
groups afforded (–)-7-epi-hyacinthacine C5 49. Having
established the synthetic pathway, Yu and co-workers
successfully synthesized (–)-6-epi-hyacinthacine C5 52 by
subjecting 44 to similar methodology. With the three
products in hand, Yu et al. reported that none of the 1H NMR
and 13C NMR spectroscopic data matched with those
reported for the natural isolate labelled (+)-hyacinthacine
C5.[50] This led to the conclusion that natural (+)hyacinthacine C5 was in fact, a different isomer. Regardless,
all synthetic isomers of this study were assayed as potential
glycosidase inhibitors and found that (–)-6-epi-hyacinthacine
C5 52 is a weak inhibitor against the α-glucosidases of rat
intestinal maltase (IC50 = 58.5 µM) and rice (IC50 = 64.2
µM).
2.7. Tamayo et al. 2011
At the same time as Yu et al. and for similar reasons,
Tamayo and co-workers also published related work
detailing a synthetic approach towards (+)-hyacinthacine C5
along with its C6, C7-diepimer.[62] Their synthesis began
with the N-Cbz protected pyrrolidine 53, a 2,5-dideoxy-2,5-

Principal Author Last Name et al.

imino-D-mannitol (DMDP) derivative (Scheme 5). In this
synthesis, the primary alcohol of 53 was initially oxidised its
corresponding aldehyde 54, which was further treated in situ
with 1-triphenylphosphoranylidene-2-propanone to afford
the α,β-unsaturated ketone 55. A non-selective
dihydroxylation of 55 with OsO4 and NMO returned a 1.4:1
separable mixture of diols 56 and 57, respectively.
Individually, both diols 56 and 57 were subjected to
reductive amination to form their respective iminium
intermediates 58 and 59. Prolonged exposure to catalytic
hydrogenation conditions over Pd/C resulted in a
stereospecific hydrogenation occurring anti to the sterically
encumbering CH2OTBDPS group of both pyrrolizidines.
More specifically, both pyrrolizidines 60 and 61 were
synthesized with the same C5-stereochemistry. Individual
global deprotections of pyrrolizidines 60 and 61, which
included a desilylation and hydrogenolysis of the benzyl
protecting groups, revealed both (+)-hyacinthacine C5 and
(+)-6,7-di-epi-hyacinthacine C5 64, respectively. Arriving to
a similar conclusion made by Yu et al., Tamayo and
colleagues also found that neither of their spectroscopic data
for hyacinthacine C5 and its C6, C7-diepimer 64 matched
that of the natural isolate[50] further suggesting it to be a
different isomer. The final products of this study were not
assessed for their glycosidase inhibitory activities.
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Scheme 3. The synthesis of unnatural hyacinthacine C1 analogues, 7a-epi-hyacinthacine C1 36 and 5,7a-di-epi-hyacinthacine C1
37 by Tamayo et al.[72]
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Scheme 4. A total synthesis of the proposed structure of (–)-hyacinthacine C5, (–)-6-epi-hyacinthacine C5 52 and (–)-7-epihyacinthacine C5 49 by Yu et al.[61]
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Scheme 5. The total synthesis of the proposed structure of (+)-hyacinthacine C5 and (+)-6,7-di-epi-hyacinthacine C5 64 by
Tamayo et al.[62]
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2.8. Fischer et al. 2014
By 2014, synthetic work towards the hyacinthacine C-type
alkaloids had revealed several structural inconsistencies
among their natural isolates. For this reason, and to also
expand the scope of information pertaining to these
compounds, Fischer and co-workers investigated the
usefulness of asymmetric 1,3-dipolar cycloadditions to
prepare optically active nitrone templates towards making
various polyhydroxylated pyrrolizidine analogues.[74] One
of the iminosugars prepared by Fischer and co-workers can
be considered an unnatural hyacinthacine C-type alkaloid
shown in Scheme 6. To obtain this analogue, Fischer et al.
began their synthesis through the preparation of the
mannose-derived nitrone 65 (Scheme 6). The cyclic nitrone
65 underwent a 1,3-dipolar cycloaddition with vinyl acetate
and afforded a 9:1 isolatable mixture of isoxazolidines,
favouring the formation of 66 for steric reasons. The acetate
moiety of 66 then underwent a SN1-like reaction with
silylketene acetal 67, which exclusively produced the 2,3atrans-isoxazolidine 68 in a 69% yield. In a two-step
procedure, the methyl ester of isoxazolidine 68 was initially
reduced with LiAlH4, then subsequently protected with tertbutyl(diphenyl)silyl chloride to give isoxazolidine 69 in
good yield (84% over two steps). The dimethyoxy ketal
moiety in compound 69 was then hydrolysed to the ketone to
give product 70, which was subjected to N-O bond reduction
and then reductive amination by hydrogenation over Pd/C to
afford the pyrrolizidine 71 as a single isomer. A global
deprotection including the removal of the silyl and the
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isopropylidene moieties returned the hexahydroxylated
pyrrolizidine 73 in 76% yield over two steps.
2.9. Vankar et al. 2014
In the same year, Vankar and co-workers reported their
synthetic work towards the synthesis of homoanologues of
hyacinthacine C5.[75] Their 2014 report details starting from
the arabinose-based cyclic nitrone 74 which underwent a 1,3dipolar cycloaddition reaction with the D-mannitol-aldehyde
derived dipolarphile 75 (Scheme 7). The desired cycloadduct
76 was obtained in a 9:1 ratio in a combined yield of 88%.
Compound 76 was then subjected to a Zn/HOAc mediated
N-O cleavage which produced the pyrrolidine 77 which then
underwent selective benzylation at the secondary amine to
give 78 in 85% over two steps. The ester moiety of 78 was
then reduced to its corresponding alcohol to afford diol 79. A
non-selective O-benzylation of both hydroxy groups
afforded 80, which upon removal of the cyclohexylidene
acetal, resulted in the formation of the diol 81. The diol
moiety of compound 81 was then oxidatively cleaved with
sodium periodate to give aldehyde 82 which was then treated
with MeMgI, returning a selective 10:1.2 mixture of
diastereomers 83a and 83b. The diastereomeric mixture was
then oxidised to the respective ketone product 84, which
after a reductive amination followed by a benzyl ether
deprotection, afforded the crude hyacinthacine C-type
analogue 86. To purify 86, Vankar et al. peracetylated the
crude mixture, followed by its deprotection. After washing
the residue with chloroform, the purified 86 was obtained.
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Scheme 6. A total synthesis of an unnatural hyacinthacine C2/3 analogue 73 by Fischer et al.[74]

Scheme 7. A total synthesis of the hyacinthacine C-type related analogue 86 by Vankar et al.[75]
2.10. Vankar et al. 2016
In continuation with synthetic efforts towards synthesizing
different unnatural analogues of bicyclic iminosugars,
Vankar et al. reported in 2016, a new strategy for accessing a
large number of complex hyacinthacine C2/3 related
products.[76] Vankar and co-workers’ synthesis of the
unnatural hyacinthacine C-type alkaloids can be summarised
in Scheme 8. Their synthetic work began with the oxidation
of pyrrolidine 87 to its corresponding aldehyde using a CrO3pyridine-Ac2O reagent system. The aldehyde formed was
then treated with allylzinc bromide to afford compound 88

which underwent O-benzylation to the product 89. The
olefin moiety of compound 89 was then subjected to a
nonselective dihydroxylation with OsO4 and NMO which
returned an inseparable mixture of diols. A selective
protection of the primary alcohol in each diol resulted in the
corresponding silyl ethers 90 and 91, which were readily
separable. To establish the methodology, Vankar and coworkers quantitatively mesylated the free hydroxy group in
compound 90. Without purification, the mesylated 90 then
underwent a N-Boc deprotection to the corresponding amine
salt, which under basic conditions furnished pyrrolizidine 92.
A global deprotection, followed by peracetylation as a means
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of purification afforded the pentaacetylate 94. After a
comprehensive structural analysis, the pentaacetylate 94 was
deprotected using aqueous ammonia in methanol which gave
the final pentahydroxlyated hyacinthacine C2/3-type analogue
96. Having established this synthetic route, Vankar and coworkers then employed a similar reaction scheme to
diastereomer 91 which successfully converted into
compound 97. Vankar et al. also readily obtained two more
epimers, 107 and 108, from subjecting pyrrolidine 98 to the
same sequence of reactions. The only notable difference is
that the hydroxy group of olefin 99 was protected as the
acetate 100 instead of the benzyl ether. Of the four
hyacinthacine C2/3 products synthesized, none matched the
putative structure for hyacinthacine C3, but they certainly
provided a better understanding towards the access to these
complex iminosugars. Additionally, the biological activities
the final products were evaluated as potential glycosidase
inhibitors against a panel of eight commercially available
enzymes. The hyacinthacine analogues 96 and 107 displayed
selective activity against jack bean α-mannosidae (IC50 =
81.2 µM and IC50 = 95 µM, respectively) with analogue 107
also displaying moderate activity against coffee bean αgalactosidase (IC50 = 120 µM). Final remarks from the
authors suggested that given these activities, hyacinthacine
analogues 96 and 107 are potential anti-diabetic and anticancer leads, respectively.
2.11. Goti et al. 2017
A recent addition towards the synthesis of the hyacinthacine
C-type alkaloids was reported in 2017 by Goti and coworkers through their synthesis of the proposed structure of
(+)-hyacinthacine C5 and its C-5 epimer 120.[63] Their goal
was to implement a straightforward and convenient synthesis
towards these complex iminosugar motifs. To access both
these structures, their convergent synthesis began with the
preparation of both the arabinose-derived cyclic nitrone 109
and
the
racemic
lithiated
3-methyl-substituted
benzyloxyallene 110 (Scheme 9). The lithiated derivative
110 was then added to nitrone 109 to form intermediate 111,
which upon standing at room temperature for 24 hours,
cyclized to afford a 1:1 separable mixture of 1,2-oxazines
112 and 113. Both oxazines were then individually subjected
to hydroboration which delivered respective alcohols 114
and 115. Goti and co-workers were initially focused on
establishing the synthetic pathway towards the proposed
structure of (+)-hyacinthacine C5 and so their attention
turned to alcohol 114 which was protected to give the pentabenzylated product 116. Next, a reductive amination of 116
with samarium diiodide in THF cleaved the N-O bond to
give the amino-alcohol, which was subsequently converted
to pyrrolizidine 118 via mesylation of the primary hydroxy
group, then spontaneous cyclization. Finally, all benzyl ether
groups were removed via hydrogenolysis to afford the
purported (+)-hyacinthacine C5. Using a similar method, 5epi-hyacinthacine C5 120 was synthesized after alcohol 115
underwent a reductive amination followed by bis-mesylation
of the hydroxy groups which concurrently cyclized to give
pyrrolizidine 119. After a LiAlH4 reduction of the sulfonyl
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group on 119, the corresponding alcohol was subjected to
hydrogenolysis to give the globally deprotected
pyrrolizidine, 5-epi-hyacinthacine C5 120.
As per the previous reports by Yu et al.[61] and Tamayo et
al.,[62] Goti and co-workers also found that the
configuration of the putative structure of hyacinthacine C5
was incorrect. Neither structure synthesized in this report
matched the spectroscopic data of the natural isolate. Despite
being unable to resolve the true structure of hyacinthacine
C5, Goti et al. revised the originally reported NOE
enhancements for the natural isolate and after finding similar
NOE correlations in their synthetic products, were able to
suggest an alternative configuration which could be
appropriately labelled as 1-epi-hyacinthacine C4 (Figure 8).

Figure 8. The NOE signals reported for the putative
hyacinthacine C5 (left) along with the revised NOE signals
proposed by Goti et al.[50, 63]
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Scheme 8. A stereodivergent synthesis of hyacinthacine C2/3 related analogues 96, 107, 97 and 108 by Vankar et al.[76]

Scheme 9. The total synthesis of the proposed structure of (+)-hyacinthacine C5 and 5-epi-hyacinthacine C5 120 by Goti et
al.[63]

2.12. Pyne et al. 2018
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Pyne and co-workers employed a flexible synthesis which is
the latest addition towards accessing the hyacinthacine Ctype alkaloids.[64] This synthetic work resulted in a total of
seven hyacinthacine C-type analogues including the total
synthesis of natural (+)-hyacinthacine C5 141 and confirmed
the hypothesis proposed by Goti et al. that its true
configuration is that of (+)-1-epi-hyacinthacine C4. In this
synthesis, Pyne et al. used a key Petasis borono Mannich
reaction at one stage to obtain the L-xylose derived anti-1,2amino alcohol 121 (Scheme 10). After protecting the
secondary amine with di-tert-butyl decarbonate to afford
122, the product was then converted to the oxazolidinone
123. Compound 123 was then subjected to ring closing
metathesis (RCM) reaction conditions which afforded the
bicyclic alkene 124 in 85% yield. The olefin moiety of
compound 124 was then subjected to a dihydroxylation
reaction with K2OsO4·H2O and NMO which afforded a 3:1
mixture of diastereomers 125a and 125b, respectively which
only separated efficiently after conversion to their acetonides
126 and 127, respectively. To establish the methodology,
acetonide 126 was hydrolysed with base under microwave
conditions to afford amino diol 128, which was subsequently
converted to the pyrrolizidine 129 in high yield after
employing Appel cyclization conditions.[77] A global
deprotection of pyrrolizidine 129 over PdCl2 followed by
basic-ion exchange chromatography resulted in the (+)-5,6di-epi-hyacinthacine C5 130. Using similar methodology,
hyacinthacine C-type analogue (‒)-5,7-di-epi-hyacinthacine
C5 133 was also obtained except that its related pyrrolizidine
core 132 was formed via selective O-mesylation, then heat
induced cyclization.
Attention was then focused on manipulating the
stereoconfiguration of the C6, C7 hydroxy groups without
affecting the stereochemistry of the A-ring in the
pyrrolizidine core (Scheme 10). To explore this chemistry,
the C8 hydroxy group in pyrrolizidine 129 was O-benzylated
and then acid hydrolysed which returned diol 135. Diol 135
was then converted to its cyclic sulfate 136 followed by a
subsequent ring opening with CsOBz (prepared in situ from
Cs2CO3 and BzOH) which gave an inseparable 1:4 mixture
of regioisomers 137a and 137b, respectively. The mixture
was subjected to base mediated hydrolysis of the benzoate in
137a and 137b which returned isolatable diols 140 and 138,
respectively. Diols 138 and 140 were individually
debenzylated under hydrogenolysis conditions (over PdCl2),
which returned pure samples of both (+)-5-epi-hyacinthacine
C5 139 and (+)-1-epi-hyacinthacine C4 141, respectively.
Having obtained four hyacinthacine C-type alkaloids, Pyne
et al. then applied the same sequence of reactions and
conditions to a 1:2 mixture of the amino diols 121 and 142,
respectively (Scheme 11). From the 1´S-142, they secured
the putative structure of (+)-hyacinthacine C5, along with
(‒)-7-epi-hyacinthacine C5 149 and (+)-6,7-di-epihyacinthacine C5 158. The spectroscopic data of all final
products were compared against the spectroscopic data of the
natural hyacinthacine C1, C4 and C5 alkaloids. It was
discovered that (+)-1-epi- hyacinthacine C4 141 matched
both 1H NMR and 13C NMR spectroscopic data and had
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similar specific optical rotations when compared with the
natural isolate labelled hyacinthacine C5. The authors found
that their spectroscopic data for synthetic (+)-hyacinthacine
C5,[61-63] (‒)-7-epi-hyacinthacine C5[61] 149 and (+)-6,7di-epi-hyacinthacine C5[62] 158 confirmed the proposed
structures and absolute configurations of the literature
reported synthetic products (+)-hyacinthacine C5, (–)-7-epihyacinthacine C5 49 and (+)-6,7-di-epi-hyacinthacine C5 64,
respectively. However, when they compared their synthetic
(+)-5-epi-hyacinthacine C5 139 against the same compound
120 reported by Goti et al., Pyne and co-workers found
several spectroscopic differences that led them to conclude
that they were not the same product. To try and resolve this
issue, they extensively characterised the peraccetylated
derivative of (+)-5-epi-hyacinthacine C5 139 as well as its
HCl salt, although neither were a spectroscopic match to the
product proposed by Goti et al. Pyne acknowledged the
possibility of a double inversion of amino diols 128, 131 or
147 after O-mesylation, and so would retain stereochemistry
in the corresponding pyrrolizidine structures. Given their
structures for synthetic (+)-hyacinthacine C5, 149 and 158
were consistent with the previously reported structures for
(+)-hyacinthacine C5[61], (–)-7-epi-hyacinthacine C5[61] 49
and (+)-6,7-di-epi-hyacinthacine C5[62] 64, they were
confident this did not occur. In contrast, Goti and co-workers
successfully synthesised the proposed structure of
hyacinthacine C5 but did not employ the same conditions to
obtain its C5 epimer. Instead they cyclized the bis-mesylated
amino product 117 and so there is the possibility that
cyclization could afford the stable 4-membered bicyclic Nheterocycle.[78] This issue has not yet been resolved and so
highlights the difficulty often associated with assigning the
structures of the hyacinthacine C-type alkaloids. Further
investigation is certainly required.
Despite this, Pyne and co-workers evaluated the final
products as potential glycosidase inhibitors. They found that
130 and 133 showed weak inhibition of the α-glucosidase of
rat intestinal isomaltase (IC50 values of 20 µM and 42 µM,
respectively) and moderate inhibition against the αglucosidase of rat intestinal sucrase (IC50 values of 13 µM
and 9.9 µM, respectively). Compound 130 proved to be a
weak inhibitor against yeast α-glucosidase (IC50 value of 83
µM) and rat intestinal maltase (IC50 value of 61 µM) but
showed moderate activity against amylglucosidases from A.
niger and Rhizopus sp (IC50 values of 25 µM and 16 µM,
respectively). Compound 149 seemed relatively inactive but
compound 139 displayed moderate inhibition against αglucosidases of rat intestinal maltase and human lysosome
(IC50 values of 21 µM and 15 µM, respectively) and weak
inhibition against the amylglucosidase of A. niger (IC50 value
of 41 µM). Besides 139, only the putative (+)-hyacinthacine
C5 was noted to display a weak inhibition against the α-Lrhamnosidase of Penicillium decumbens (IC50 value of 74
µM). Pyne and co-workers noted a correlation between the
orientation of the C5 methyl group and the IC50 against each
enzyme tested. More specifically, if the hyacinthacine C-type
alkaloid contained an (5S)-methyl then the IC50 values
increased with consequently a reduction in the selectivity
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and potency of the compound as a glycosidase inhibitor.
Comparatively, for a decrease in the IC50, the hyacinthacine
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C-type alkaloids containing an (5R)-methyl proved more
suitable candidates as potential glycosidase inhibitors.

Scheme 10. The total synthesis of (+)-5,6-di-epi-hyacinthacine C5 130, (‒)-5,7-di-epi-hyacinthacine C5 133, (+)-5-epihyacinthacine C5 139 and (+)-1-epi-hyacinthacine C4 141.[64]
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Scheme 11. The total synthesis of (‒)-7-epi-hyacinthacine C5 149, (+)-hyacinthacine C5, (+)-6,7-di-epi-hyacinthacine C5
158.[64]
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3. CONCLUSIONS
Research towards pyrrolizidine alkaloid isolation and
synthesis is of paramount importance. From an economic
point of view, characterisation of these compounds is
essential to prevent illness occurring in livestock and more
importantly, humans. The polyhydroxylated pyrrolizidine
alkaloids containing a C-3 methyl or hydroxymethyl
represent only a slight fraction of the ever-growing number
of discovered pyrrolizidine alkaloids but are of great
importance as they are potentially medicinally useful. Of
these, the hyacinthacine C-type alkaloids have generated
recent interest which can be attributed to their inherent
glycosidase inhibitory activities, making this class of
compound suitable candidates for anti-diabetic, anti-obesity,
anti-cancer and in some cases, anti-bacterial drug scaffolds.
Their high degree of oxidation in conjunction with complex
stereochemistry presents as a rewarding synthetic feat for
any laboratory prepared to undertake their synthesis and is
beginning to rapidly grow as a research area. Additionally, a
number of mistakes associated with their structures warrants
their synthesis as a way to confirm or correct their proposed
structures. To date, methods of total synthesis have
confirmed the structure of hyacinthacine C2 to be correct but
has found that the structure for hyacinthacine C3 requires
revision. The structures for hyacinthacine C1 and
hyacinthacine C4 remain insecure since they both contain
different spectroscopic data but have been assigned the same
relative stereochemistry. Pyne et al. recently confirmed the
hypothesis by Goti and co-workers, by synthesizing the
correct structure for hyacinthacine C5 found to be (+)-1-epihyacinthacine C4. However, their spectroscopic data for (+)5-epi-hyacinthacine C5 139 when compared against the same
compound 120 reported by Goti et al., did not match and so
requires further investigation. Despite these issues, the
studies reported in this review have resulted in the synthesis
of important regio- and stereo-isomers of the hyacinthacine
C-type compounds and so presents as a great significance to
the large community interested in the preparation of
glycosidase inhibiting and consequent therapeutic
iminosugars. Unfortunately, the glycosidase activities of a
number of these analogues remains uncertain as they were
not evaluated for their biological activity. This observation
suggests the need for an accessible approach for assaying
these compounds as potential drug motifs for the
aforementioned illnesses and complications. Although they
may not ever be marketable drugs, synthetic access and
glycosidase testing of the hyacinthacine C-type alkaloids
represent a positive step towards understanding the structureactivity-relationship of a glycosidase active site mechanisms.
This foundation prepares the knowledge base required to
eventually design marketable drugs that manage and
selectively treat the aforementioned illnesses with minimal
side effects.
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